Catalyst Pharmaceuticals saw an improvement in its IBD SmartSelect Composite Rating Tuesday, from 94 to 96.
Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets
The upgrade means the stock is now outpacing 96% of all other stocks in terms of key performance metrics and technical strength.
Catalyst Pharmaceuticals is not currently near a proper buy point. See if the stock goes on to form a new base and offer a new buying opportunity.
The stock has a 99 EPS Rating, which means its recent quarterly and annual earnings growth tops 99% of all stocks.
Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.
In Q1, the company posted 79% earnings growth. Sales growth increased 44%, up from 28% in the prior report. That marks four consecutive reports with increasing revenue gains. The company's next quarterly report is expected on or around Aug. 6.
Catalyst Pharmaceuticals earns the No. 6 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Incyte and Inhibrx Biosciences are among the top 5 highly-rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
